Teva’s New ESG Strategy
Amalia Adler Waxman, VP Global head of ESG at Teva Pharmaceuticals, discusses Teva’s new 2030 goals and the centrality of the new corporate ESG strategy as part of that.
The new ESG strategy covers 21 topics and 8 priorities:
Environment: GHG emissions, waste, water and antimicrobial resistance
Social: access to medicine, inclusion & diversity and employee engagement
Governance: Ethics and ESG in the supply chain
According to Adler-Waxman, Covid 19 highlighted the social role of companies and specifically the importance of pharmaceutical companies. 2020 also witnessed a significant rise in investors’ interest in ESG.
During Covid Teva focused on its employees’ wellbeing but made sure that manufacturing lines were open and operative.